Gliaid MP 1 Tablet SR is a combination oral hypoglycemic agent containing Glimepiride (1mg), Metformin (500mg), and Pioglitazone (15mg), formulated for sustained release to improve glycemic control in patients with type 2 diabetes mellitus. Glimepiride, a sulfonylurea, stimulates pancreatic beta-cell insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and enhances peripheral insulin sensitivity, contributing to improved glucose uptake and utilization. Pioglitazone, a thiazolidinedione, acts as an insulin sensitizer by activating peroxisome proliferator-activated receptor gamma (PPAR-γ), which modulates the transcription of insulin-responsive genes involved in glucose and lipid metabolism. The combination of these agents targets multiple pathophysiological defects in type 2 diabetes, offering complementary mechanisms to achieve optimal glycemic control. Gliaid MP 1 Tablet SR is indicated as an adjunct to diet and exercise to improve glycemic control in adults inadequately controlled on monotherapy or dual therapy. It should be used with caution in patients with hepatic or renal impairment and contraindicated in those with known hypersensitivity to any component, severe renal dysfunction, or diabetic ketoacidosis. Regular monitoring of blood glucose, liver function, and renal parameters is recommended during therapy to ensure safety and efficacy.